Globus Medical, Inc. with ticker code (GMED) now have 13 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $115.00 and $80.00 suggesting an average analyst share price target price of $94.23. (at the time of writing). Now with the previous closing price of $82.63 and the analysts are correct then we can expect a percentage increase in value of 14.0%. It’s also worth noting that there is a 50 day moving average of $79.73 and the 200 moving average now moves to $68.11. The market capitalization for the company is 11.32B. Currently the stock stands at: $83.10 USD
The potential market cap would be $12,904,105,708 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 134.03, revenue per share of $18.22 and a 4.73% return on assets.
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions. The Company’s product categories include Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics (INR) solutions for assisted surgery.
